Ratio de rentabilidad sobre activos (ROA)
desde 2012
Cálculo
Zoetis Inc., ROA, tendencias a largo plazocálculo
| ROA | = | 100 | × | Beneficio neto atribuible a Zoetis1 | ÷ | Activos totales1 | |
|---|---|---|---|---|---|---|---|
| 31 dic. 2023 | 16.41% | = | 100 | × | 2,344) | ÷ | 14,286) |
| 31 dic. 2022 | 14.16% | = | 100 | × | 2,114) | ÷ | 14,925) |
| 31 dic. 2021 | 14.65% | = | 100 | × | 2,037) | ÷ | 13,900) |
| 31 dic. 2020 | 12.04% | = | 100 | × | 1,638) | ÷ | 13,609) |
| 31 dic. 2019 | 12.99% | = | 100 | × | 1,500) | ÷ | 11,545) |
| 31 dic. 2018 | 13.25% | = | 100 | × | 1,428) | ÷ | 10,777) |
| 31 dic. 2017 | 10.06% | = | 100 | × | 864) | ÷ | 8,586) |
| 31 dic. 2016 | 10.73% | = | 100 | × | 821) | ÷ | 7,649) |
| 31 dic. 2015 | 4.28% | = | 100 | × | 339) | ÷ | 7,913) |
| 31 dic. 2014 | 8.82% | = | 100 | × | 583) | ÷ | 6,607) |
| 31 dic. 2013 | 7.69% | = | 100 | × | 504) | ÷ | 6,558) |
| 31 dic. 2012 | 6.96% | = | 100 | × | 436) | ÷ | 6,262) |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31).
1 US$ en millones
Comparación con la competencia
Zoetis Inc., ROA, tendencias a largo plazo, comparación con los competidores
| Zoetis Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31 dic. 2023 | 16.41% | 3.61% | 6.91% | 8.43% | 5.64% | 8.19% | 9.12% | 20.98% | 0.34% | 0.94% | 11.95% | 6.07% |
| 31 dic. 2022 | 14.16% | 8.53% | 10.06% | 6.53% | 8.55% | 12.62% | 7.27% | 9.57% | 13.30% | 15.91% | 14.85% | 7.15% |
| 31 dic. 2021 | 14.65% | 7.88% | 9.63% | 6.40% | 7.73% | 11.44% | 9.16% | 11.47% | 12.35% | 12.11% | 31.75% | 8.12% |
| 31 dic. 2020 | 12.04% | 3.07% | 11.54% | -7.61% | 4.79% | 13.28% | 0.18% | 8.41% | 7.72% | 6.23% | 20.47% | 9.23% |
| 31 dic. 2019 | 12.99% | 8.84% | 13.13% | 2.65% | 4.85% | 21.17% | 8.74% | 9.59% | 11.66% | 9.72% | 14.29% | 6.33% |
| 31 dic. 2018 | 13.25% | 9.58% | 12.64% | 14.06% | 5.54% | 7.36% | 8.57% | 10.00% | 7.53% | 7.00% | 20.83% | 5.22% |
| 31 dic. 2017 | 10.06% | 7.50% | 2.48% | 3.00% | 5.34% | -0.45% | 6.58% | 0.83% | 2.72% | 12.40% | 13.67% | 3.93% |
| 31 dic. 2016 | 10.73% | 9.01% | 9.95% | 13.22% | 5.64% | 7.05% | 23.70% | 11.71% | 4.11% | 4.20% | 12.84% | 4.40% |
| 31 dic. 2015 | 4.28% | 9.70% | 9.69% | 4.93% | 6.96% | 6.77% | 34.93% | 11.55% | 4.36% | 4.16% | 11.34% | 4.83% |
| 31 dic. 2014 | 8.82% | 6.44% | 7.47% | 5.94% | 7.02% | 6.43% | 34.91% | 12.45% | 12.12% | 5.40% | 8.99% | 4.42% |
| 31 dic. 2013 | 7.69% | 14.14% | 7.68% | 6.64% | 7.77% | 13.29% | 13.67% | 10.42% | 4.17% | 12.78% | 14.38% | 4.00% |
| 31 dic. 2012 | 6.96% | 19.53% | 8.00% | 5.46% | 7.26% | 11.89% | 12.20% | 8.94% | 5.81% | 7.84% | 36.06% | 4.29% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31).
Comparación con el sector industrial: Productos farmacéuticos, biotecnología y ciencias de la vida
Zoetis Inc., ROA, tendencias a largo plazo, comparación con el sector industrial: productos farmacéuticos, biotecnología y ciencias de la vida
| Zoetis Inc. | Productos farmacéuticos, biotecnología y ciencias de la vida | |
|---|---|---|
| 31 dic. 2023 | 16.41% | 7.19% |
| 31 dic. 2022 | 14.16% | 10.59% |
| 31 dic. 2021 | 14.65% | 10.39% |
| 31 dic. 2020 | 12.04% | 5.34% |
| 31 dic. 2019 | 12.99% | 9.02% |
| 31 dic. 2018 | 13.25% | 8.84% |
| 31 dic. 2017 | 10.06% | 5.32% |
| 31 dic. 2016 | 10.73% | 8.68% |
| 31 dic. 2015 | 4.28% | 8.98% |
| 31 dic. 2014 | 8.82% | 9.58% |
| 31 dic. 2013 | 7.69% | 9.54% |
| 31 dic. 2012 | 6.96% | 8.34% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31).
Comparación con la industria: Atención médica
Zoetis Inc., ROA, tendencias a largo plazo, comparación con la industria: atención médica
| Zoetis Inc. | Atención médica | |
|---|---|---|
| 31 dic. 2023 | 16.41% | 6.42% |
| 31 dic. 2022 | 14.16% | 8.35% |
| 31 dic. 2021 | 14.65% | 8.24% |
| 31 dic. 2020 | 12.04% | 5.46% |
| 31 dic. 2019 | 12.99% | 7.22% |
| 31 dic. 2018 | 13.25% | 6.17% |
| 31 dic. 2017 | 10.06% | 5.34% |
| 31 dic. 2016 | 10.73% | 6.95% |
| 31 dic. 2015 | 4.28% | 7.35% |
| 31 dic. 2014 | 8.82% | 8.18% |
| 31 dic. 2013 | 7.69% | 8.28% |
| 31 dic. 2012 | 6.96% | 7.68% |
Basado en los informes: 10-K (Fecha del informe: 2023-12-31), 10-K (Fecha del informe: 2022-12-31), 10-K (Fecha del informe: 2021-12-31), 10-K (Fecha del informe: 2020-12-31), 10-K (Fecha del informe: 2019-12-31), 10-K (Fecha del informe: 2018-12-31), 10-K (Fecha del informe: 2017-12-31), 10-K (Fecha del informe: 2016-12-31), 10-K (Fecha del informe: 2015-12-31), 10-K (Fecha del informe: 2014-12-31), 10-K (Fecha del informe: 2013-12-31), 10-K (Fecha del informe: 2012-12-31).